A股異動丨CRO板塊集體下挫,美生物安全法案向前推進
美國參議院國土安全委員會通過法案,可能限制部分中國生物科技公司開展業務。A股CRO板塊集體下跌,藥明康德觸及跌停,康龍化成跌超8%,凱萊英跌超5%,泰格醫藥跌超4%,九洲藥業、誠達藥業跌超3%。美國參議院國土安全委員會以國家安全為由投票通過法案,可能限制與華大基因和藥明康德等中國生物科技公司開展業務。該法案旨在防止外國對手獲取美國人的個人健康和遺傳訊息。該委員會以11比1的投票結果批准推進這個法案草案。法案仍須在參議院和眾議院全體會議上獲得通過,然後需要總統簽署。藥明康德週三在一份電子郵件聲明中表示,該公司不收集基因數據,該法案“依靠誤導性指控和不準確的斷言,在未經正當程序的情況下對我們公司提出先發制人和不合理的禁令”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.